DURHAM, N.C. — Dova Pharmaceuticals, Inc. is having a bit of a management shakeup.
Most recently, it has appointed David Zaccardelli as president and chief executive officer, replacing Alex Sapir, effective immediately.
Prior to his appointment, Dr. Zaccardelli served in several senior management roles at United Therapeutics Corporation.
In addition, Jason Hoitt, a pharmaceutical sales and marketing executive, will join Dova as chief commercial officer. He formerly served as vice president and head of U.S. sales at Insmed Inc. since 2017, and held roles at Sarepta Therapeutics from 2013 to 2017, including head of U.S. Sales and senior director of Medical Affairs.
Dova Pharma’s revenue, loss beats analysts’ expectations but shares drop
“We are very pleased to have both Dr. David Zaccardelli and Jason Hoitt join Dova, as they are highly experienced leaders with the expertise to accelerate the ongoing launch of DOPTELET, prepare for the potential launch in chronic immune thrombocytopenia (ITP), and oversee the clinical development of the chemotherapy-induced thrombocytopenia indication,” Paul B. Manning, chairman of Dova, said in a statement. “We believe we have a strong team in place to lead Dova into its next phase of growth.”
“I strongly believe it is a transformational time to join Dova to ensure the full potential of DOPTELET, the first orally administered option for the treatment of thrombocytopenia in patients with chronic liver disease (CLD),” added Dr. Zaccardelli. “In addition, the recently submitted supplemental New Drug Application for patients with ITP provides an opportunity for substantial growth, with the potential for a significant impact on the treatment for patients with ITP. Dova will continue its focus on developing new treatments for patients with unmet medical need.”
Separately, the company provided preliminary estimates of expected net product sales of $2.4 to $2.7 million for DOPTELET for the fourth quarter of 2018.
The company also expects any change in year-end inventory held by specialty pharmacies to be flat or potentially decrease compared to the inventory levels on September 30, 2018. The company intends to provide additional detail, including specific metrics, on its fourth quarter and full year 2018 earnings call.
